Navigation Links
Genzyme Delivers Strong Fourth Quarter to Conclude Outstanding Year
Date:2/13/2008

new products-Renvela(R)

(sevelamer carbonate) in the United States, Synvisc-ONE(TM) (hylan

G-F 20) and Cholestagel(R) (colesevelam hydrochloride) in the

European Union, and Elaprase(R) (idursulfase) in Japan-and secured

expanded U.S. labeling for Campath(R) (alemtuzumab) and Thyrogen(R)

(thyrotropin alfa for injection).

-- Reported highly encouraging clinical trial results for two key late

stage product candidates: Mozobil(TM) (plerixafor) for stem-cell

transplantation and alemtuzumab for multiple sclerosis.

Fourth-Quarter 2007 Highlights

-- Revenue increased 21 percent in the fourth quarter to $1.04 billion, up

from $854.2 million in the prior fourth quarter.

-- GAAP net income increased to $78.9 million, or $0.29 per diluted share,

compared with an acquisition-related net loss of $268.2 million, or

$1.02 per diluted share, in the prior fourth quarter.

-- Non-GAAP net income increased 19 percent to $249.2 million, compared

with $209.0 million in the previous fourth quarter.

-- Non-GAAP earnings rose 18 percent to $0.91 per diluted share from

$0.77. The increased operating expenses and decreased interest income

associated with Genzyme's fourth-quarter acquisition of Bioenvision

reduced earnings by $0.01 per diluted share. The company had noted

previously that the impact of this transaction would be reflected in

its fourth-quarter results.

-- Individual product sales for the fourth quarter and the year, along

with expectations for the longer-term growth of Genzyme's business

segments, were detailed in a January 8, 2008, press release coinciding

with the company's presentation at the JPMorgan Healthcare Conference.

"We delivered outstanding financial results last year while continuing to build the company to meet our goa
'/>"/>

SOURCE Genzyme Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24

Related medicine news :

1. Genzyme Receives FDA Response Letter on Synvisc-One(TM)
2. Bioenvision Shareholders Approve Acquisition by Genzyme Corporation
3. Genzyme Statement Regarding Results of FDA Advisory Committee Meeting on the Use of Phosphate Binders in Chronic Kidney Disease
4. Genzyme and Bayer Schering Pharma AG, Germany to Present New Data on Alemtuzumab in Multiple Sclerosis at ECTRIMS
5. Delaware Court Approves Bioenvision, Genzyme Joint Petition
6. Elliott Extremely Dissatisfied With Genzyme Bid for Bioenvision; Believes Offer Significantly Undervalues Company
7. Liquent Insight Publisher 3.6 Delivers Advanced Submission Capabilities
8. March of Dimes Delivers a New Look
9. Independence Blue Cross Delivers Important Reminder to Women during Cervical Cancer Awareness Month
10. PARIs eFlow Delivers Alnylam RNAi Therapeutic in Phase I Study
11. Gleevec, the targeted cancer pill, delivers more good news to patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... PHILADELPHIA For rats bearing human breast tumors, exposure ... to the breast cancer drug tamoxifen, according to data ... the American Association for Cancer Research. The negative effects ... by giving rats a melatonin supplement during the night. ... patients with hormone receptor-positive breast cancer," said Steven M. ...
(Date:7/24/2014)... Denver, CO (PRWEB) July 24, 2014 Ticket ... vs. AS Roma Tickets in Denver at the Sports Authority ... Champions Cup (or World Football Challenge) has brought some of the ... a mini-tournament. With the World Cup still being raved about weeks ... have the chance to see some of the biggest stars in ...
(Date:7/24/2014)... New York (PRWEB) July 24, 2014 ... lawsuits ( http://www.injurybeacon.com/granuflo-dialysis/lawsuit/ ) in the U.S. ... qualified protective order for plaintiff medical information covered ... Act. According to the July 16th Order, U.S. ... attorneys for Fresenius Medical Care the right ...
(Date:7/24/2014)... (ASAE) announced its 2014 Power of A Award winners, ... Anesthesiologists (ASA). , The ASA Global Humanitarian Outreach ... one of the top honors from ASAE. GHO was ... through education on the global anesthesia crisis and supporting ... was also honored with a Power of A Silver ...
(Date:7/24/2014)... 24, 2014 Pools and beaches are the ... can be dangerous, especially for small children, so Amica ... , According to the Centers for Disease Control and Prevention, ... at risk for water-related injuries and deaths. It’s important to ... water, so Amica is offering the following tips from the ...
Breaking Medicine News(10 mins):Health News:Exposure to dim light at night may make breast cancers resistant to tamoxifen 2Health News:Manchester United vs. AS Roma Tickets Denver Sports Authority Field at Mile High: Ticket Down Cuts Ticket Prices for Guinness International Champions Cup Match 2Health News:Manchester United vs. AS Roma Tickets Denver Sports Authority Field at Mile High: Ticket Down Cuts Ticket Prices for Guinness International Champions Cup Match 3Health News:GranuFlo Lawsuits Move Forward in Federal Court, With Issuance of Protective Order for HIPAA Information, Bernstein Liebhard LLP Reports 2Health News:GranuFlo Lawsuits Move Forward in Federal Court, With Issuance of Protective Order for HIPAA Information, Bernstein Liebhard LLP Reports 3Health News:GranuFlo Lawsuits Move Forward in Federal Court, With Issuance of Protective Order for HIPAA Information, Bernstein Liebhard LLP Reports 4Health News:Keep Kids Safe in the Water with 5 Tips from Amica 2
... Oct. 9 Actor Joe Pantoliano,reveals a personal ... mother,struggled with untreated bipolar disorder, in a guest ... National Alliance on Mental,Illness (NAMI)., Pantoliano,s entry ... a few days before the opening of his ...
... shows , TUESDAY, Oct. 9 (HealthDay News) -- U.S. ... to a treatment for the hereditary, progressive neurological disorder ... molecule called C2-8 appears to reduce HD-related neurological damage ... team from the MassGeneral Institute for Neurological Disorders (MIND), ...
... heart attack risk, study finds , , TUESDAY, Oct. 9 (HealthDay ... who has had a heart attack will have another major ... shown that workplace stress boosts heart woes, but this is ... and other major events, the report,s authors said. , The ...
... Johns Hopkins scientists have developed a potentially novel way ... potent barrages of radiation inside cancer cells, unlike current ... attack from the outside and cause unwanted side effects. ... cells, the new radiation delivery system proved able to ...
... The March of,Dimes congratulates Mario R. Capecchi, Ph.D., ... D.Phil., FRS, former recipients of the,March of Dimes Prize ... Physiology or Medicine. The Nobel Committee announced yesterday ... principles for introducing specific gene,modifications in mice by the ...
... Health plans are expecting premium,rate increases in 2008 ... of 8.2%. This is the fourth consecutive decline in ... survey in September of 2007. The survey,contained 76 responses, ... Separately, the survey notes that the East South Central ...
Cached Medicine News:Health News:Actor Joe Pantoliano Discloses Depression; Talks About His Latest Movie and His Sensitive Side 2Health News:Molecule Promising Against Huntington's Disease 2Health News:Stressful Jobs Hard on the Heart 2Health News:Stressful Jobs Hard on the Heart 3Health News:Inside job: new radioactive agents for colon cancer work inside cells 2Health News:Nobel Honors 3 Former March of Dimes Prize Recipients 2
(Date:7/24/2014)... Consolidated Net Profit increased by 43.65 % ... , India Business grew by 20.87% to Rs. 3,971.59 ... Mn Rest of World (ROW) Business grew by 20.67% ... 34.53% to Rs. 977.26 Mn Latin America Business grew ... Glenmark Pharmaceuticals Limited, the research-led global integrated pharmaceutical company, today announced ...
(Date:7/24/2014)... 24, 2014 /PRNewswire-iReach/ -- Delivery of the Report ... placed. Photo - http://photos.prnewswire.com/prnh/20140723/129707 ... in-depth market survey on Global and Chinese Hemodialysis ... information of Hemodialysis Machine including its classification, application ... and China,s top manufacturers of Hemodialysis Machine listing ...
(Date:7/24/2014)... 2014 Cancer patients in the west of ... treatment closer to home when a new radiotherapy center opens ... Systems (NYSE: VAR ) has been selected to ... June for four TrueBeam™ medical linear accelerators. ... efficient radiotherapy and radiosurgery treatments, will replace older treatment machines ...
Breaking Medicine Technology:Glenmark's Consolidated Revenue Increases by 20.08% to Rs. 14,869.40 Mn for Q1 FY 14 - 15 2Glenmark's Consolidated Revenue Increases by 20.08% to Rs. 14,869.40 Mn for Q1 FY 14 - 15 3Glenmark's Consolidated Revenue Increases by 20.08% to Rs. 14,869.40 Mn for Q1 FY 14 - 15 4Hemodialysis Machine Industry for Global and Chinese Markets Forecast to 2019 2Hemodialysis Machine Industry for Global and Chinese Markets Forecast to 2019 3Hemodialysis Machine Industry for Global and Chinese Markets Forecast to 2019 4Hemodialysis Machine Industry for Global and Chinese Markets Forecast to 2019 5Varian Medical Systems Selected to Equip First Satellite Radiotherapy Center in Scotland 2Varian Medical Systems Selected to Equip First Satellite Radiotherapy Center in Scotland 3
... Mass., Dec. 8, 2010 Decision Resources, one ... for pharmaceutical and healthcare issues, finds that although ... of care for first- and second-line treatment of ... replace paclitaxel/carboplatin as the standard second-line treatment for ...
... 8, 2010 Sunridge International (OTC Bulletin Board: ... preparing to start the short term clinical trials needed ... L.L.C., Sunridge,s exclusive distributor for several Middle Eastern countries, ... to attend the start of their clinical trials.  Dr. ...
Cached Medicine Technology:For the Treatment of Ovarian Cancer, Pegylated Liposomal Doxorubicin/Carboplatin Will Replace Paclitaxel/Carboplatin as the Standard Second-Line Treatment for Platinum Sensitive Patients 2For the Treatment of Ovarian Cancer, Pegylated Liposomal Doxorubicin/Carboplatin Will Replace Paclitaxel/Carboplatin as the Standard Second-Line Treatment for Platinum Sensitive Patients 3
... Aaron manufactures two groups of flexible lighting ... and non-sterile in three different sizes 5", ... shaft portion of the light). These lights ... light is needed., ,The second group ...
... manufactures two groups of flexible lighting products. ... non-sterile in three different sizes 5", 10", ... portion of the light). These lights are ... is needed., ,The second group of ...
These units, though small, still offer sufficient output to ensure current is fully adjustable from 0 to 70 mA. Instruction manual, ball electrodes, battery and leads with alligator clips are include...
... Modes of Operation: , Double Burst : 2 60-ms ... Twitch: 1 s (1 pulse/s) , Tetanus: 50 ... , Train-Of-Four: Single (4 pulses/2 s) , Output Current: ... Wave Monophasic pulses (200-us duration) , Indicators: Battery LED ...
Medicine Products: